Incannex Healthcare

Edison Investment Research has terminated coverage on Incannex Healthcare (IXHL). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: The next phase of the obesity market

Edison explains: The cost of insecure infrastructure

Have autos hit the brakes too hard?

Audiovisual

Latest

Webinar – SCHMID Group: Inside the Industry

Freelancer – executive interview

BlackRock Greater Europe Investment Trust – equity proposition

About Edison

Corporates

Investors

Careers

Incannex Healthcare (NASDAQ: IXHL)

Latest Insights

Incannex Healthcare — Spotlight on Incannex’s progress in psychedelics

Incannex Healthcare — On the road to psychotherapy clinics

Incannex Healthcare — On to Phase II for IHL-675A

Incannex Healthcare — A clinically active quarter

Market Data

Sector

Incannex Healthcare — IHL-42X gearing up for FDA studies

Incannex Healthcare — An encouraging start to the new financial year

Incannex Healthcare — Positive Phase I data for IHL-675A

Incannex Healthcare — Constructive pre-IND FDA meeting for IHL-216A

Incannex Healthcare — Targeting FDA studies in FY23

Incannex Healthcare — Addressing unmet needs via alternative approach

Incannex Healthcare — APIRx acquisition to bolster portfolio